中国全科医学2018，Vol.21Issue(9)：1047-1052,6.DOI:10.3969/j.issn.1007-9572.2017.00.210
华蟾素胶囊联合盐酸埃克替尼片治疗晚期非小细胞肺癌临床效果研究
Effect of Cinobufacini Capsule Combined with Lcotinib in the Treatment of Advanced Non-small Cell Lung Cancer
摘要
Abstract
Objective To evaluate the efficacy of cinobufotalin capsules combined with lcotinib on advanced non-small-cell lung cancer (NSCLC) patients in terms of treatment outcome, quality of life. Methods We enrolled 76 cases of advanced NSCLC received treatment in Department of Respiratory Medicine, Zhoushan Hospital from January 2014 to June 2016 and divided them into two groups based on the random number table: treatment group (n=38) and control group (n=38). Both groups received 3-month lcotinib treatment (125 mg, tid), the treatment group additionally received 3-month treatment with cinobufotalin capsules (500 mg, tid). At the end of treatment, the short-term efficacy, median progression-free survival (PFS), and treatment-induced adverse reactions were evaluated, and quality of life was assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. Results In the treatment group, partial remission (PR) rate was 47.4% (18/38), stable disease (SD) rate was 39.5% (15/38), and progressive disease (PD) rate was 13.1% (5/38); in the control group, PR rate was 21.1% (8/38), SD rate was 44.7% (17/38), PD rate was 34.2% (13/38). The objective response rate (ORR) of the treatment group was 47.4% (18/38), which was significantly higher than 21.0% (8/38) of the control group (χ2=6.167, P=0.015).The disease control rate (DCR) of the treatment group was 86.8% (33/38), which was significantly higher than 65.8% (25/38) of the control group (χ2=4.833, P=0.031). The incidence of disease progression / death in the treatment group was 34.2% (13/38), which was significantly higher than 13.2% (5/38) of the control group (χ2=4.659, P=0.029). The treatment group scored higher in terms of constitutional function (t=6.467, P<0.05) as well as emotional function (t=12.482, P<0.05) than the control group. Lower occurrence rates of fatigue (χ2=2.117, P<0.05) and pain (χ2=2.098, P<0.05) were identified in the treatment group. Grade Ⅲ-Ⅳrash occurred in two cases in the control group. Two groups had significant difference in the incidence of rash (Z=4.698, P<0.05). Both groups were found with one case of grade Ⅲ-Ⅳ diarrhea. Conclusion Cinobufotalin capsules combined with Icotinib can improve the treatment outcome, prolong the survival time, improve the quality of life and reduce the incidence of rash in advanced NSCLC patients.关键词
癌,非小细胞肺/华蟾素/盐酸埃克替尼/治疗结果Key words
Carcinoma,non-small-cell lung/Cinobufacini/Lcotinib/Treatment outcome分类
医药卫生引用本文复制引用
周磊,邵燕儿,朱泽浩,李略,李海峰,王辉..华蟾素胶囊联合盐酸埃克替尼片治疗晚期非小细胞肺癌临床效果研究[J].中国全科医学,2018,21(9):1047-1052,6.基金项目
舟山市科技局基金资助项目(2013C31061)—海岛地区晚期NSCLC患者胸水EGFR基因突变及EGFR-TKIs疗效观察 （2013C31061）
